comparemela.com

Latest Breaking News On - Lineage cell therapeutics inc - Page 18 : comparemela.com

Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that the Company is expected to be added to the. | May 22, 2023

Hematopoietic Stem Cells Transplantation (HSCT) Market to grow by USD 2,383 61 million from 2023 to 2027, North America to account for 40% of the market growth

Lineage Cell Therapeutics, Inc to Post FY2027 Earnings of $0 00 Per Share, HC Wainwright Forecasts (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Rating) – Equities research analysts at HC Wainwright raised their FY2027 earnings per share (EPS) estimates for Lineage Cell Therapeutics in a research note issued to investors on Friday, May 12th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of $0.00 per share […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.